TP53 and breast neoplasm: The occurrence of breast tumor in TP53-carrying women is remarkably high with a cumulative incidence at 60 years of 85%; screening suggests clinical breast surveillance every 6–12 months starting from 20 years of age, annual breast MRI with contrast from 20 to 75 years, and annual mammography from 30 to 75 years [42,46].